Exagen raises 2026 revenue outlook to $72M-$75M as profitability nears

Exagen reported record second-quarter revenue of $19.9 million, up 16% year-over-year, and raised its full-year 2026 revenue outlook to $72–$75 million as the diagnostics company nears profitability. CEO John Aballi highlighted record quarterly AVISE test volume and trailing 12-month average selling price, alongside improved margins, during the earnings call. The company's raised guidance reflects sustained growth in its core autoimmune testing franchise. Exagen's path to breakeven remains tied to managing key risks, including reimbursement rates and competitive pressures in the specialty diagnostics market. The company continues to focus on commercial execution to achieve sustained profitability.